-
1
المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin
المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Associationمصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test -
2
المؤلفون: Piotr Rutkowski, Sama Ahsan, Jean-Jacques Grob, Matteo S. Carlino, James R. Anderson, Merrick I. Ross, John M. Kirkwood, Jeffrey E. Gershenwald, Caroline Robert, Jason J. Luke, Nageatte Ibrahim, Charles H. Yoon, Peter Mohr, Georgina V. Long, Alexander M.M. Eggermont, Axel Hauschild, Paolo A. Ascierto, Andrew Poklepovic, Richard A. Scolyer
المصدر: Future Oncology. 16:4429-4438
مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Adolescent, medicine.medical_treatment, Dermatologic Surgical Procedures, Programmed Cell Death 1 Receptor, Pembrolizumab, Antibodies, Monoclonal, Humanized, Placebo, Disease-Free Survival, Placebos, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Adjuvant therapy, Humans, Multicenter Studies as Topic, 030212 general & internal medicine, Young adult, Child, Melanoma, Neoplasm Staging, Randomized Controlled Trials as Topic, Cross-Over Studies, business.industry, General Medicine, medicine.disease, Crossover study, Clinical trial, Clinical Trials, Phase III as Topic, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Adjuvant
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6a00dd1a28f82ed3c8216b416ba2d53Test
https://doi.org/10.2217/fon-2019-0666Test -
3
المؤلفون: Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
المساهمون: University Medical Center [Utrecht], Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), N.N. Blokhin National Medical Research Center of Oncology, Edith Cowan University (ECU), Royal Marsden NHS Foundation Trust, Universitat de Barcelona (UB), Instituto de Salud Carlos III [Madrid] (ISC), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Merck & Co. Inc, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Institut Gustave Roussy (IGR), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Internal medicine, CCA - Cancer Treatment and quality of life
المصدر: EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045Test(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Groupمصطلحات موضوعية: Male, Skin Neoplasms, Medizin, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, 80 and over, MESH: Double-Blind Method, 030212 general & internal medicine, Neoplasm Metastasis, Humanized, Melanoma, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Adult, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Neoplasm Staging, medicine.medical_specialty, MESH: Melanoma, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, education, Cancer staging, MESH: Humans, business.industry, MESH: Skin Neoplasms, MESH: Adult, MESH: Neoplasm Metastasis, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208Test
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027Test -
4
المؤلفون: Adil Daud, Jeffrey S. Weber, Georgina V. Long, Matteo S. Carlino, Jacob Schachter, Wen-Jen Hwu, Peter Hersey, Caroline Robert, Antoni Ribas, Le Min, Nageatte Ibrahim, Celine Boutros, Igor Puzanov, Jianxin Lin, Scott J. Diede, F. Stephen Hodi, Reinhard Dummer, Omid Hamid, Richard W. Joseph, Roxana S. Dronca, Jedd D. Wolchok, Tara C. Mitchell, Anthony M. Joshua
المساهمون: Intégrité du génome, ARN et cancer, Institut Curie [Paris]-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), University of Zurich, Robert, Caroline
المصدر: European journal of cancer (Oxford, England : 1990)
European Journal of Cancer
European Journal of Cancer, Elsevier, 2021, 144, pp.182-191. ⟨10.1016/j.ejca.2020.11.010⟩مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, [SDV]Life Sciences [q-bio], Immune-checkpoint inhibitors, Pembrolizumab, Gastroenterology, 0302 clinical medicine, Antineoplastic Agents, Immunological, Immune-related adverse events, Monoclonal, 80 and over, 1306 Cancer Research, Melanoma, Humanized, Cancer, Aged, 80 and over, Clinical Trials as Topic, 10177 Dermatology Clinic, Middle Aged, Prognosis, Advanced melanoma, 3. Good health, Immunological, Oncology, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, Toxicity, Public Health and Health Services, 2730 Oncology, Female, PD-1 inhibitors, Adult, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Oncology and Carcinogenesis, 610 Medicine & health, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Article, Antibodies, Vaccine Related, 03 medical and health sciences, Young Adult, Meta-Analysis as Topic, Internal medicine, medicine, Humans, In patient, Oncology & Carcinogenesis, Adverse effect, Pneumonitis, Aged, Immunomodulating drugs, business.industry, Evaluation of treatments and therapeutic interventions, medicine.disease, Clinical trial, 030104 developmental biology, Corticosteroid use, Immunization, business, Follow-Up Studies
وصف الملف: application/pdf; 868_Robert_C._et_al._Long-term_safety_of_pembrolizumab_monotherapy_and_relationship_with_clinical_outcome_EJC_2020.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c081e1b4e51d5ab8b097204bced3e77dTest
https://escholarship.org/uc/item/275859csTest -
5
المؤلفون: James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser
المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
European Journal of Cancer, 116, 148-157مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
https://hdl.handle.net/2066/206244Test -
6
المؤلفون: Jean-Jacques Grob, Michal Lotem, Christian U. Blank, Catriona M. McNeil, Jacob Schachter, James Larkin, Adil Daud, Omid Hamid, Laurent Mortier, Ana Arance, Matteo S. Carlino, Bart Neyns, Paul Lorigan, Shu Chih Su, Antoni Ribas, Teresa M. Petrella, Georgina V. Long, Clemens Krepler, Caroline Robert, Nageatte Ibrahim
المساهمون: Clinical sciences, Medical Oncology, Laboratory for Medical and Molecular Oncology, Laboratory of Molecullar and Cellular Therapy
مصطلحات موضوعية: Adult, Male, 0301 basic medicine, advanced melanoma, medicine.medical_specialty, Phases of clinical research, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Progression-free survival, ipilimumab, KEYNOTE-006, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, Medicine(all), business.industry, Proportional hazards model, Hazard ratio, Middle Aged, Progression-Free Survival, Clinical trial, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, pembrolizumab, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b24205b257822ddbf30cee39b4dc1f9Test
https://biblio.vub.ac.be/vubirTest/(e2696151-46a7-4118-9960-b3e5b06df058).html -
7
المؤلفون: Ana Arance, Thomas F. Gajewski, Christian Caglevic, Mark M. Jones, Janet Maleski, Caroline Robert, Lev V. Demidov, Omid Hamid, Tae Min Kim, Scott J. Diede, Stéphane Dalle, Tara C. Mitchell, Matteo S. Carlino, Reinhard Dummer, Georgina V. Long, James R. Anderson, Jean-Jacques Grob, James Larkin
المساهمون: University of Zurich, Long, Georgina V
المصدر: Ann Transl Med
مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Population, 610 Medicine & health, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Progression-free survival, education, Melanoma, Aged, education.field_of_study, Sulfonamides, business.industry, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, Interim analysis, Progression-Free Survival, Clinical trial, Editorial Commentary, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Female, 2730 Oncology, business
وصف الملف: 805_Long_GV._et_al._Epacadostat_plus_pembrolizumab_versus_placebo_plus_pembrolizumab_in_patients_with_unresectable_or_metastatic_melanoma_etc._Lancet_Oncol_2019.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994d50fe36f67262fd59a66df91baccbTest
https://www.zora.uzh.ch/id/eprint/172887Test/ -
8
المؤلفون: Christian U. Blank, Scot Ebbinghaus, Reinhard Dummer, Carmen Loquai, Steven J. O'Day, Antoni Ribas, Adil Daud, Jacob Schachter, Caroline Robert, Janice M. Mehnert, Dirk Schadendorf, S. Peter Kang, Wei Zhou, Igor Puzanov, Darcy A. Hille, April K.S. Salama, Omid Hamid, Lee D. Cranmer, Alfons J.M. van den Eertwegh, Axel Hauschild
المساهمون: University of Zurich, Schadendorf, Dirk, Medical oncology, CCA - Clinical Therapy Development
المصدر: Schadendorf, D, Dummer, R, Hauschild, A, Robert, C, Hamid, O, Daud, A, van den Eertwegh, A, Cranmer, L, O'Day, S, Puzanov, I, Schachter, J, Blank, C, Salama, A, Loquai, C, Mehnert, J M, Hille, D, Ebbinghaus, S, Kang, S P, Zhou, W & Ribas, A 2016, ' Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma ', European Journal of Cancer, vol. 67, pp. 46-54 . https://doi.org/10.1016/j.ejca.2016.07.018Test
European Journal of Cancer, 67, 46-54. Pergamonمصطلحات موضوعية: Male, Cancer Research, Skin Neoplasms, Health Status, Health-related quality of life, medicine.medical_treatment, Medizin, Pembrolizumab, Carboplatin, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, 030212 general & internal medicine, Melanoma, Aged, 80 and over, 10177 Dermatology Clinic, Middle Aged, Advanced melanoma, Dacarbazine, Oncology, 030220 oncology & carcinogenesis, Female, 2730 Oncology, medicine.drug, Adult, KEYNOTE-002, medicine.medical_specialty, Adolescent, Paclitaxel, 610 Medicine & health, Ipilimumab, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Young Adult, 03 medical and health sciences, Refractory, Internal medicine, Temozolomide, medicine, Humans, Chemotherapy, In patient, Patient Reported Outcome Measures, Aged, Patient-reported outcomes, business.industry, Cancer, EORTC QLQ-C30, medicine.disease, Surgery, Quality of Life, business, Ipilimumab-refractory melanoma
وصف الملف: 663_Schadendorf D. et al._Health-related quality of life in the randomised KEYNOTE-002_EJC 2016.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0340a48931fc5ff52f9246c04eeed519Test
https://doi.org/10.1016/j.ejca.2016.07.018Test -
9
المؤلفون: Nageatte Ibrahim, Richard W. Joseph, Caroline Robert, Roxana S. Dronca, Adil Daud, Tara C. Mitchell, Jedd D. Wolchok, Omid Hamid, Richard F. Kefford, Jeffrey S. Weber, Antoni Ribas, Qing Zhao, Erin Jensen, Amita Patnaik, Anthony M. Joshua, F.S. Hodi, W. Hwu, Peter Hersey, Hassane M. Zarour, Sama Ahsan
المصدر: Annals of oncology : official journal of the European Society for Medical Oncology, vol 30, iss 4
Annals of Oncologyمصطلحات موضوعية: 0301 basic medicine, Skin Neoplasms, long-term follow-up, Pembrolizumab, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Agents, Immunological, Monoclonal, Humanized, Melanoma, Cancer, treatment-naive, Hematology, metastatic, Immunological, Oncology, Tolerability, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, pembrolizumab, Adult, medicine.medical_specialty, Patients, overall survival, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Antibodies, Drug Administration Schedule, Time, Vaccine Related, 03 medical and health sciences, Clinical Research, Internal medicine, medicine, Overall survival, melanoma, Humans, Oncology & Carcinogenesis, Until Disease Progression, Response Evaluation Criteria in Solid Tumors, Advanced melanoma, business.industry, Evaluation of treatments and therapeutic interventions, Original Articles, medicine.disease, Discontinuation, Clinical trial, Editor's Choice, 030104 developmental biology, business, Follow-Up Studies
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4525cdc4a9d2f1fea9bc8b0ee243f7Test
https://pubmed.ncbi.nlm.nih.gov/30768148Test -
10
المؤلفون: Laurent Dercle, Caroline Robert, Samy Ammari, François Janot, Stéphan Vagner, Caroline Rossoni, Ruth Gabriela Herrera Gómez, Jean-Yves Scoazec, Séverine Roy, Antoine Moya-Plana, Alexander M.M. Eggermont, Isabelle Girault
المصدر: Cancer immunology, immunotherapy : CII. 68(7)
مصطلحات موضوعية: Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Immunology, Programmed Cell Death 1 Receptor, Ipilimumab, Pembrolizumab, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Immunology and Allergy, Humans, CTLA-4 Antigen, Prospective Studies, Stage (cooking), Prospective cohort study, Melanoma, Aged, Retrospective Studies, Aged, 80 and over, Mucous Membrane, business.industry, Mucosal melanoma, Immunotherapy, Middle Aged, medicine.disease, Prognosis, Confidence interval, Progression-Free Survival, Cutaneous melanoma, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ba22fb8cdfc15b10f1cd10b8cb29c45Test
https://pubmed.ncbi.nlm.nih.gov/31172258Test